Vaxart (OTCMKTS:VXRT) Stock Crosses Below Two Hundred Day Moving Average - Should You Sell?

Key Points

• Vaxart shares fell below their 200-day moving average of $0.62, trading as low as $0.4705 and last changing hands at $0.4940.
• Zacks Research upgraded the stock to “Hold,” matching the consensus rating from the one analyst covering Vaxart.
• Vaxart exceeded quarterly expectations, reporting an EPS loss of $0.06 versus the expected $0.12 loss and revenue of $27.18 million versus $26.21 million expected; institutional investors own 18.05% of the company.

Vaxart, Inc. (OTCMKTS:VXRT - Get Free Report)'s share price crossed below its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $0.62 and traded as low as $0.4705. Vaxart shares last traded at $0.4940, with a volume of 547,262 shares traded.

Wall Street Analyst Weigh In

Separately, Zacks Research upgraded Vaxart to a "hold" rating in a report on Thursday, July 9th. One analyst has rated the stock with a Hold rating, Based on data from MarketBeat.com, the stock presently has an average rating of "Hold".

Vaxart Stock Performance

The stock has a market cap of $119.96 million, a price-to-earnings ratio of 3.09 and a beta of 1.10. The stock's 50-day simple moving average is $0.55 and its two-hundred day simple moving average is $0.62.

Vaxart (OTCMKTS:VXRT - Get Free Report) last released its quarterly earnings results on Thursday, August 6th. The biotechnology company reported ($0.06) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.12) by $0.06. The company had revenue of $27.18 million during the quarter, compared to analysts' expectations of $26.21 million. Vaxart had a net margin of 15.88% and a return on equity of 53.04%. As a group, research analysts predict that Vaxart, Inc. will post -0.68 earnings per share for the current year.

Institutional Trading of Vaxart

Several hedge funds have recently added to or reduced their stakes in VXRT. Creative Planning acquired a new stake in Vaxart in the 2nd quarter valued at approximately $33,000. Goldman Sachs Group Inc. bought a new position in Vaxart in the 1st quarter worth approximately $31,000. Invesco Ltd. lifted its holdings in shares of Vaxart by 93.1% during the first quarter. Invesco Ltd. now owns 146,366 shares of the biotechnology company's stock worth $60,000 after buying an additional 70,568 shares during the last quarter. Raymond James Financial Inc. lifted its holdings in shares of Vaxart by 16.9% during the second quarter. Raymond James Financial Inc. now owns 236,166 shares of the biotechnology company's stock worth $107,000 after buying an additional 34,075 shares during the last quarter. Finally, Jones Financial Companies Lllp boosted its position in shares of Vaxart by 276,364.7% in the first quarter. Jones Financial Companies Lllp now owns 478,284 shares of the biotechnology company's stock valued at $196,000 after acquiring an additional 478,111 shares during the period. Institutional investors own 18.05% of the company's stock.

About Vaxart

Vaxart, Inc is a clinical-stage biotechnology company pioneering the development of oral recombinant vaccines administered in tablet form. Leveraging a proprietary, room-temperature-stable platform, the company aims to simplify vaccine delivery while eliciting both systemic and mucosal immune responses. Its technology is based on the replication-defective adenovirus vector system, which encodes target antigens designed to protect against a range of infectious diseases without the need for injections or cold-chain logistics.

The company’s pipeline includes multiple vaccine candidates in various stages of development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source